<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798627</url>
  </required_header>
  <id_info>
    <org_study_id>824109</org_study_id>
    <nct_id>NCT02798627</nct_id>
  </id_info>
  <brief_title>Trial Of NS2359 For The Treatment of Cocaine Dependence</brief_title>
  <official_title>A Phase II, Double-Blind, Placebo-Controlled, Trial Of NS2359 For The Treatment of Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saniona</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Dana Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NS2359 attenuates the euphoria associated with cocaine use. In a manner parallel to cocaine,&#xD;
      NS2359 blocks the reuptake of dopamine (DA), norepinephrine (NE), and serotonin (5HT) with&#xD;
      nanomolar affinities at the 3 transporters. In primates NS2359 significantly attenuated&#xD;
      cocaine self-administration. In several phase II clinical trials for major depressive&#xD;
      disorder and adult attention deficit disorder, NS2359 did not cause euphoria. NS2359&#xD;
      exhibited no abuse potential in a human laboratory study comparing NS2359 with amphetamine.&#xD;
      In a phase I human laboratory interaction study, NS2359 showed no toxicity after 20 or 40 mg&#xD;
      of cocaine, but it attenuated the both the rewarding and cardiovascular effects of&#xD;
      intravenous cocaine. On the basis of these promising studies, investigators propose a Phase&#xD;
      II double-blind clinical trial of NS2359 in cocaine addiction (CA). The proposed trial will&#xD;
      involve 100 CA subjects participating in an eight week trial, including a 1-week baseline and&#xD;
      8 weeks of NS2359 or placebo treatment. Four weeks after completing the medication phase,&#xD;
      there will be one follow-up visit. Subjects will be randomly assigned to treatment with&#xD;
      placebo or 2 mg NS2359 daily, with a possible decrease to 1 mg daily for adverse events. This&#xD;
      dose range is selected on the basis of phase I and II evidence of tolerability and NS2359&#xD;
      plasma levels which were associated with blockade of cocaine reward. This project has the&#xD;
      potential to identify the first effective pharmacotherapy for CA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II randomized double-blind, placebo-controlled trial, 40 persons will be&#xD;
      randomized to NS2359 and 40 to placebo. The primary hypothesis is: more NS2359-treated&#xD;
      subjects (compared to placebo-treated subjects) will achieve 3 consecutive weeks of cocaine&#xD;
      abstinence, as measured by urine benzoylecgonine (BE) assay, during the last three weeks of&#xD;
      the trial. The study is 9 weeks: one week of screening, followed by an 8-week double-blind,&#xD;
      placebo-controlled trial. All subjects will receive weekly cognitive behavioral therapy (CBT)&#xD;
      to encourage abstinence during their 3 times weekly clinic visits. Investigators expect ~ 20%&#xD;
      dropout rate, based on our recent CA clinical trials (eg, Kampman et al, 2015 and 2013), so&#xD;
      80 randomized patients will yield ~ 64 study completers. There will be a 1 month start-up&#xD;
      period, followed by 20 months of recruitment for the study. The 1 month start-up period will&#xD;
      allow for training of staff, preparation of study capsules, placement of study&#xD;
      advertisements, etc. Penn IRB approval has been obtained. There will be a 2-month termination&#xD;
      period to allow the final patients to complete the study. Data cleaning, statistical analyses&#xD;
      and preparation of reports will be done in the final two months. Based on recent cocaine&#xD;
      pharmacotherapy trials conducted by our team, monthly enrollment of ~4 CA participants&#xD;
      (respondents to flyers and advertisements) is feasible.&#xD;
&#xD;
      Recruitment will occur at the University of Pennsylvania's Treatment Research Center (TRC),&#xD;
      led by Kyle Kampman, MD, and Wade Berrettini, MD, PhD, Professors of Psychiatry at Penn. At&#xD;
      the TRC, CA patients are respondents to advertisements for free treatment of CA. The&#xD;
      ethnicity is 90% African-American, 9 % European-American, 70% male, mean age 47 (+/- 12).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">October 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants Who Achieved Abstinence From Cocaine During the Last Three Weeks of the Trial</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of Participants Who Report no Cocaine Use and Have no Cocaine Positive Urine Drug Screens in the NS2359 Group Versus the Placebo Group Comparator During the Last Three Weeks of the Trial [ Time Frame: weeks 6,7.8 of the trial ] Number of subjects with cocaine abstinence as measured through three-times-weekly urine benzoylecgonine (BE) levels in urine drug screen (UDS) and self-reports of use from the Time Line Follow Back. UDS results and TLFB reports combined to yield weekly use/no-use indicators for each week of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Weekly Cocaine Craving Scores NS2359 Group Versus the Placebo Group Comparator [ Time Frame: Once Per Week in Weeks 2 Through 8 ]</measure>
    <time_frame>8 weeks</time_frame>
    <description>As measured by average weekly scores for cocaine craving on the brief substance craving scale combining cocaine craving frequency, intensity and duration. Minimum value 0 maximum value 12 higher scores indicate worse craving.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Cocaine Use Disorder</condition>
  <arm_group>
    <arm_group_label>NS2359</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NS2359</intervention_name>
    <description>NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.</description>
    <arm_group_label>NS2359</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo pills identical in appearance to the NS2359 will be provided</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and females, 18-65 years old.&#xD;
&#xD;
          2. Meets diagnostic criteria (DSM-V) for current diagnosis of cocaine use disorder,&#xD;
             moderate to severe, by semi-structured interview.&#xD;
&#xD;
          3. In the past 30 days, used no less than $100-worth of cocaine&#xD;
&#xD;
          4. Speaks, understands, and prints in English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Meets DSM-V criteria for substance use disorder, moderate to severe, for a substance&#xD;
             other than cocaine, alcohol or nicotine. Subjects with comorbid alcohol use disorder&#xD;
             will be accepted if their alcohol use disorder is not severe enough to require a&#xD;
             medical alcohol detoxification.&#xD;
&#xD;
          2. Needs treatment with any psychoactive medications (with the exception of&#xD;
             diphenhydramine or melatonin, if necessary, for sleep).&#xD;
&#xD;
          3. Meets current or lifetime DSM-V criteria for schizophrenia or any psychotic disorder,&#xD;
             or organic mental disorder.&#xD;
&#xD;
          4. Has another Axis I psychiatric disorder that in the opinion of the physician will&#xD;
             interfere with completion of the study or place the patient at heightened risk through&#xD;
             participation in the trial.&#xD;
&#xD;
          5. Has evidence of a history of significant hematological, pulmonary, endocrine,&#xD;
             cardiovascular, renal or gastrointestinal disease.&#xD;
&#xD;
          6. Use of an investigational medication in the 30 days prior to randomization.&#xD;
&#xD;
          7. Is female and has a positive pregnancy test, is contemplating pregnancy in the next 6&#xD;
             months, is nursing, or is not using effective contraception (if relevant).&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wade Berrettini, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Perelman School of Medicine, Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <results_first_submitted>April 3, 2021</results_first_submitted>
  <results_first_submitted_qc>May 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 24, 2021</results_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Kyle Kampman</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02798627/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment by advertising in local newspapers and radio began in 07/2016 and ended in 12/2018.</recruitment_details>
      <pre_assignment_details>Participants had a screening telephone appointment to determine eligibility. If eligible, they were seen at the clinic for history, physical exam and urine drug screen. A positive urine drug screen for a cocaine metabolite (BE) was used as a stratifying variable in randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NS2359</title>
          <description>The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.&#xD;
NS2359: NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.&#xD;
placebo: Placebo pills identical in appearance to the NS2359 will be provided</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NS2359</title>
          <description>The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.&#xD;
NS2359: NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.&#xD;
placebo: Placebo pills identical in appearance to the NS2359 will be provided</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" lower_limit="49.5" upper_limit="59.6"/>
                    <measurement group_id="B2" value="52" lower_limit="49.8" upper_limit="56.9"/>
                    <measurement group_id="B3" value="53.8" lower_limit="49.6" upper_limit="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days of cocaine use in past 30</title>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" lower_limit="4.0" upper_limit="20"/>
                    <measurement group_id="B2" value="9.5" lower_limit="5.0" upper_limit="17.0"/>
                    <measurement group_id="B3" value="9.0" lower_limit="5.0" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants Who Achieved Abstinence From Cocaine During the Last Three Weeks of the Trial</title>
        <description>Number of Participants Who Report no Cocaine Use and Have no Cocaine Positive Urine Drug Screens in the NS2359 Group Versus the Placebo Group Comparator During the Last Three Weeks of the Trial [ Time Frame: weeks 6,7.8 of the trial ] Number of subjects with cocaine abstinence as measured through three-times-weekly urine benzoylecgonine (BE) levels in urine drug screen (UDS) and self-reports of use from the Time Line Follow Back. UDS results and TLFB reports combined to yield weekly use/no-use indicators for each week of treatment.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NS2359</title>
            <description>The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.&#xD;
NS2359: NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.&#xD;
placebo: Placebo pills identical in appearance to the NS2359 will be provided</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Achieved Abstinence From Cocaine During the Last Three Weeks of the Trial</title>
          <description>Number of Participants Who Report no Cocaine Use and Have no Cocaine Positive Urine Drug Screens in the NS2359 Group Versus the Placebo Group Comparator During the Last Three Weeks of the Trial [ Time Frame: weeks 6,7.8 of the trial ] Number of subjects with cocaine abstinence as measured through three-times-weekly urine benzoylecgonine (BE) levels in urine drug screen (UDS) and self-reports of use from the Time Line Follow Back. UDS results and TLFB reports combined to yield weekly use/no-use indicators for each week of treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.97</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Weekly Cocaine Craving Scores NS2359 Group Versus the Placebo Group Comparator [ Time Frame: Once Per Week in Weeks 2 Through 8 ]</title>
        <description>As measured by average weekly scores for cocaine craving on the brief substance craving scale combining cocaine craving frequency, intensity and duration. Minimum value 0 maximum value 12 higher scores indicate worse craving.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NS2359</title>
            <description>The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.&#xD;
NS2359: NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.&#xD;
placebo: Placebo pills identical in appearance to the NS2359 will be provided</description>
          </group>
        </group_list>
        <measure>
          <title>Average Weekly Cocaine Craving Scores NS2359 Group Versus the Placebo Group Comparator [ Time Frame: Once Per Week in Weeks 2 Through 8 ]</title>
          <description>As measured by average weekly scores for cocaine craving on the brief substance craving scale combining cocaine craving frequency, intensity and duration. Minimum value 0 maximum value 12 higher scores indicate worse craving.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="0.39"/>
                    <measurement group_id="O2" value="3.89" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was measured over 12 weeks</time_frame>
      <desc>Patients completed adverse event forms and answered specific questions about adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>NS2359</title>
          <description>The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.&#xD;
NS2359: NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.&#xD;
placebo: Placebo pills identical in appearance to the NS2359 will be provided</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <description>heart racing</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>increased blood pressure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of individuals analyzed. Some noncompliance per plasma NS2359 levels at mid and end treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kyle Kampman, MD</name_or_title>
      <organization>University of Pennsylvania Perelman School of Medicine</organization>
      <phone>2157462764</phone>
      <email>kampman@pennemdicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

